ArticleJournal, genetic engineering & biotechnology2026
Multinomial risk modeling of osteopenia and osteoporosis in Iraqi women: comparative contributions of osteoprotegerin and vitamin D3.
Article in Journal, genetic engineering & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionVitamin D status is frequently low among Iraqi women, which may limit its discriminatory value for osteopenia (ON) and osteoporosis (OP). We evaluated the vitamin D axis (VD3, DBP, and VDR), osteoprotegerin (OPG), and endocrine regulators (estradiol [E2] and parathyroid hormone [PTH]) in relation to ON/OP risk before and after menopause. MATERIALS AND
methodsIn this cross-sectional study, 120 women were classified as control, ON, or OP (n = 40 each) based on DEXA-derived T-scores. Serum VD3, DBP, VDR, OPG, E2, and PTH were measured by ELISA. Group comparisons were conducted using ANOVA with post hoc testing, and adjusted odds ratios (OR) for ON and OP were estimated using multinomial logistic regression, controlling for age and BMI.
resultsIn premenopausal women, E2 and OPG were significantly lower in ON and OP than in controls (E2: p < 0.001; OPG: p = 0.001), whereas VD3, VDR, and DBP did not differ significantly. In postmenopausal women, OPG was markedly lower in OP than in controls and ON (p < 0.001), while VDR and DBP remained non-significant; VD3 showed a decreasing trend in OP (p = 0.042). In adjusted multinomial regression, OPG was strongly protective against OP (OR 0.275; 95% CI 0.172-0.441; p < 0.001) and against ON (OR 0.724; 95% CI 0.538-0.973; p = 0.033). E2 was protective against OP (OR 0.491; 95% CI 0.356-0.676; p < 0.001) and against ON (OR 0.748; 95% CI 0.608-0.920; p = 0.006). VD3 showed a modest protective association with OP (OR 0.948; 95% CI 0.901-0.998; p = 0.040) but not with ON, while PTH was a slight risk factor for OP (OR 1.027; 95% CI 1.004-1.051; p = 0.021).
conclusionIn Iraqi women, particularly after menopause, OPG (and E2) showed a stronger and more consistent association with OP/ON risk than VD3, whereas DBP and VDR were not informative in this cohort. These findings support OPG as a promising biomarker for osteoporosis risk stratification in populations with prevalent vitamin D insufficiency.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.